Problem: Lower limb ulceration is a common problem in clinical practice. A variety of
metabolic and physical causes can lead to a diversity of chronic ulcer types, including …

Chronic nonhealing diabetic foot ulcers are a common medical problem that may precede
severe complications such as infection, sepsis and limb loss. Current standard methods of …

Dermagraft is three-dimensional, allogeneic, human neonatal dermal fibroblast culture
grown on a degradable scaffold and cryopreserved. Clinical trials for treatment of diabetic …

We have created two skin products at Advanced Tissue Sciences: a nonliving wound
covering called Trans-Cyte, and Dermagraft, which consists of living cells. In March 1997 …

Biologically-based skin substitutes have developed as commercial products over the last 5
years. The first generation includes the collagen-based synthetic device, Integra, and …

OBJECTIVE—To determine if a human fibroblast–derived dermal substitute could promote
the healing of diabetic foot ulcers. RESEARCH DESIGN AND METHODS—A randomized …

OBJECTIVE To assess the effect of a tissue-engineered human dermis (Dermagraft) in
healing diabetic foot ulcers. RESEARCH DESIGN AND METHODS This controlled …

Background. A number of different treatment approaches have been recommended for the
treatment of venous ulceration, including local ulcer treatment, compression and drug …

Tissue-engineered biological dressings offer promise in the treatment of burns, chronic
ulcers, donor site and other surgical wounds, and a variety of blistering and desquamating …

Background: Apligraf is a bioengineered skin product composed of neonatal fibroblasts and
keratinocytes. The FDA has approved Apligraf for the treatment of chronic venous ulcers and …